Research & Development

Promoting the expansion of advanced cell therapies

01

Committed to the future

Advances in the fields of medicine and life sciences are only possible through continuous investment by companies and institutions in R&D.

Investments of over 2 million euros in research associated with cell therapy are the evidence of Stemlab’s commitment to the development of new solutions to increase the number of therapeutic applications of stem cells.

Stemlab aims to run 3 clinical trials by 2018, one of which should be close to finish phase 2 at that time.

Achieving this ambition is based on 3 key aspects:

  • A highly specialised team, made up of professionals in the field of life sciences

  • The consolidation of a strong network of partnerships

  • Cutting edge infrastructure with conditions to develop and manufacture products for cell therapies

Imagem ID_01

Our R&D Team

  • André Gomes, Biochemist, Responsible for R&D Department
  • Carla Cardoso, Doctor of Pharmacy, with a specialization in Biochemistry, Researcher and Project Manager in the R&D Department
  • Margarida Vieira, Doctor of Biochemistry, with a specialization in Molecular Biology, Researcher and Project Manager in the R&D Department
  • Teresa Matos, Doctor of Biology, with a specialization in Cell Biology, Researcher and Project Manager in the R&D Department

03

Projects

Stemlab’s R&D team and its partners have developed a set of projects aimed at expanding the clinical application of stem cells from umbilical cord tissue and blood.

940x200

Two patents for stem cell treatments

Stemlab currently has two registered patents as a result of its research and development efforts. It is one of the first European companies to hold patents for treatments based on stem cells.

Find out more


  • WoundcordNUP: ECOMP-01-0202-FEDER-030318

    A partnership with the Coimbra Centre for Neuroscience and Cell Biology and Biocant, in the field of the joint application of umbilical cord blood stem cells with endothelial progenitor cells in patients with chronic wounds, with the purpose of improving their healing by decreasing inflammation and increasing revascularization of the area affected by the wound.


  • InjectcordNUP: CENTRO – 07-0202–FEDER–005476

    Developed in partnership with Dr. Lino Ferreira from the Coimbra Centre for Neuroscience and Cell Biology and Biocant, this partnership aims to develop new platforms for isolated cell transplants using umbilical cord blood, to allow cardiac regeneration after ischaemic problems.

     
    Developed in partnership with Dr. Lino Ferreira (Centre for Neuroscience and Cell Biology of Coimbra and Biocant) this project aimed at developing new platforms for the transplantation of umbilical cord blood cells to promote cardiac regeneration after ischaemic events.
    INJECTCORD was developed between 2009 and 2012 and was supported by EU Funding. The goal of this project was to develop a gel for local application of umbilical cord blood stem cells in order to stimulate regeneration.
    This project had excellent performance and results, and gave rise to two patent applications (patents pending). The value of this intellectual property is currently being developed in new projects, aiming at the development of clinical applications in the field of regenerative medicine, particularly in wound healing in chronic diabetic patients.


  • IsocordNUP: CENTRO – 07-0202–FEDER–005547

    Working in the field of optimisation and characterisation of mesenchymal stem cells from umbilical cord tissue, the objective of this project, run as a partnership between researchers from Biocant, the national Histocompatibility Centre and the Higher Technical Institute, is to provide support for the expansion of hematopoietic stem cells in transplant and neural regeneration cases.

     
    Developed in partnership with researchers from Biocant, national Histocompatibility Centre and the Higher Technical Institute (University of Lisbon), this project aimed to isolate and characterize the mesenchymal stem cells (MSCs) from the umbilical cord (blood and matrix) and to explore their potential in hematopoietic stem cells’ expansion and in neural regeneration.
    The project, supported with EU Funding, was developed between 2009 and 2012.
    ISOCORD aimed to demonstrate that the umbilical cord (cord blood and cord matrix) is a promising source of MSCs, and can be a viable alternative to bone marrow as a cell source for various therapeutic applications. Accordingly, in addition to the cryopreservation of umbilical cord blood in public or private banks, the establishment of efficient protocols for the cryopreservation of umbilical cord itself and / or its derived MSCs is also scientifically supported.
    As a result of this project, Stemlab developed a proprietary method for processing and isolating the MSCs from the umbilical cord matrix. Stemlab is the only company in Europe with an international accreditation for this type of service.


  • Cell expansion

    Aimed at developing a method to increase the number of hematopoietic stem cells in samples of umbilical cord blood, to ensure the viability of transplants in adults, in partnership with the Higher Technical Institute (University of Lisbon).


  • ExocordNUP: FCOMP-01-0202-FEDER-038631

    This project aims to assess the therapeutic effect of growth factors released by stem cells from umbilical cord blood in the healing of chronic wounds in an animal model of diabetes.


  • aDVANCeNUP: FCOMP-01-0202-FEDER-038870

    Co-developed with CEDOC – Chronic Diseases Research Center (Nova University of Lisbon), the aim of the project is to develop new cancer treatments.